Nexus Pharmaceuticals has launched cyclophosphamide injection in ready-to-dilute vials. Read what this means for oncology workflows and generic drug access.
Evommune is taking EVO756 into migraine prophylaxis. Read why MRGPRX2 inhibition could matter, and what risks still cloud the story.
Delcath Systems won ESMO-EURACAN guideline recognition for CHEMOSAT in uveal melanoma. Read what this could change for liver-directed cancer care.
Vascarta’s VAS-101 showed early knee osteoarthritis pain benefits. Read what the data changes, what remains unclear, and what to watch next.
Tenvie Therapeutics begins Phase 1 dosing of TNV262. Find out why this CNS-penetrant NLRP3 inhibitor could reshape obesity and CVD treatment.
Can Oncolytics Biotech move pelareorep closer to approval in anal cancer? Read what the FDA meeting could change for clinicians and investors.
Caliway’s CBL-514 heads to ADA 2026 with tirzepatide combination data. Read what this could change in obesity treatment strategy.
Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.
Glenmark Pharmaceuticals is taking direct control of Ryaltris in the U.S. Read what this shift means for allergy drug strategy and specialty growth.
AvenCell Therapeutics has dosed the first AVC-203 patient in QUADvance. Read what this means for allogeneic CAR-T and B-cell cancer treatment.